

# AGENDA

**10:00 - 10:05 AM**

**Welcome & Expectations**

Jim Crone, *President of Board of Directors*

**10:05 - 10:15 AM**

**Opening Remarks from FDA**

Dr. Michelle Campbell, *Division of Neurology*

**10:15 - 10:25 AM**

**Brief overview of CIDP**

**Mechanisms & Diagnosis**

Dr. Peter Donofrio, *Global Medical Advisory Board Chair*

**10:25 - 10:35 AM**

**Current Landscape of CIDP**

**Treatment Options**

Dr. Jeff Allen, *Global Medical Advisory Board Member*

**10:35 - 11:30 AM**

**Patient Panel 1: Diagnosis &**

**Current Treatment Options**

**MODERATOR:** Dr. Mamatha Pasnoor, *Global Medical Advisory Board Member*

**PANELISTS:** Crystal Sada, Julie Bell, Barry Fortner, Diana Christian

**11:35 AM - 12:30 PM**

**Patient Panel 2:**

**Everyday Burden of CIDP**

**MODERATOR:** Lisa Butler, *Executive Director*

**PANELISTS:** Michele Dearing, Kelly McCoy, Jon Schandler, Victor Sheronas

**12:30 - 12:45 PM - BREAK**

**12:45 - 1:40 PM**

**Patient Panel 3:**

**CIDP Trial Design**

**MODERATOR:** Dr. Mamatha Pasnoor

**PANELISTS:** Betsy Blake, Lynn Rogers, Dave Rosner, Dave Tuck

**1:45 - 2:40 PM**

**Patient Panel 4: Potential Future of CIDP Treatments**

**MODERATOR:** Lisa Butler

**PANELISTS:** Nancy DiSalvo, Angela Patton, Linda Paul, Corbin Whittington

**2:40 - 2:45 PM - BREAK**

**2:45 - 3:00 PM**

**Summary of the Meeting**

**Closing Remarks**

Lisa Butler

# Voice OF THE PATIENT SUMMIT



**FRIDAY, MARCH 25, 2022**

## Externally-Led Patient Focused Drug Development Meeting on CIDP

The GBS|CIDP Foundation International is leading the effort to characterize the patient journey and bring the patient voice into the drug development process. We will continue to utilize a patient-reported information registry and robust support and education programming to accurately describe the patient experience that also encourages self-advocacy in both clinical and research settings. The Foundation hopes that an externally-led Patient Focused Drug Development meeting will elevate the CIDP patient voice and increase understanding of patients' preferences when it comes to tolerable side effects, most hindering symptoms of CIDP, and a better understanding of the progressive disability associated with poorly managed CIDP. Ultimately, the Foundation aims to bring the patient voice into the drug development process. Learn more now at [www.gbs-cidp.org/voice-of-the-patient-summit/](http://www.gbs-cidp.org/voice-of-the-patient-summit/).

To the right is our Patient Centric Program Agenda for the EL-PFDD on March 25, 2022. All are welcome to attend this virtual event. Times listed reflect Eastern Standard Time Zone (EST).

### OUR SPONSORS

